Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1345 • 2019 ACR/ARP Annual Meeting
Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?
Sadao Jinno¹, Akira Onishi ², Kengo Akashi ², Motomu Hashimoto ³, Wataru Yamamoto ³, Koichi Murata ³, Tohru Takeuchi ⁴, Takuya Kotani ⁴, Yuichi Maeda ⁵, Kosuke Ebina ⁶, Yonsu Son ⁷, Hideki Amuro ⁷, Ryota Hara ⁸, Masanori Katayama ⁹, Jun Saegusa ² and Akio Morinobu ², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan, ⁵Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁷First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ⁸The Center for Rheumatic Disease, Department of Orthopedic Surgery, Nara Medical University, Nara, Japan, ⁹Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan
Background/Purpose: To compare efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Methods: Patients with…
Abstract Number: 1372 • 2019 ACR/ARP Annual Meeting
Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis
Gisele Alejandra Luna¹, fernando dal Pra ², Emilce Schneeberger ³, Leonela Lysseth Macias Oviedo ⁴ and Gustavo Citera ⁵, ¹Instituto de Rehabilitación Psicofísica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Instituto Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The adherence to the therapeutic regimen in patients with Rheumatoid Arthritis (RA) varies between 30 and 80%. Classically, it is mentioned that the adherence…
Abstract Number: 1408 • 2019 ACR/ARP Annual Meeting
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Andreas Kerschbaumer¹, Alexandre Sepriano ², Josef Smolen ¹, Désirée van der Heijde ², Maxime Dougados ³, Ronald F Van Vollenhoven ⁴, Iain McInnes ⁵, Johannes Bijlsma ⁶, Gerd Burmester ⁷, Maarten de Wit ⁸, Louise Falzon ⁹ and Robert B.M. Landewé ¹⁰, ¹Medical University of Vienna, Vienna, Austria, ²Leiden University Medical Center, Leiden, Netherlands, ³Cochin Hospital, Paris, France, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷Charité—University Medicine Berlin, Berlin, Germany, ⁸Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁹Northwell Health, New York, ¹⁰Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Via a systematic literature review of contemporary efficacy data of pharmacological therapies in RA we sought to inform the 2019 update of the EULAR…
Abstract Number: 1440 • 2019 ACR/ARP Annual Meeting
Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis
Lisa Stamp¹, Paula Keating ², Christopher Frampton ³, Murray Barclay ³, Niamh Fanning ³, Melanie Millier ⁴, Paul Hessian ⁴ and John O'Donnell ⁵, ¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²Canterbury Health Laboratories, Christchurch, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Therapeutic drug monitoring (TDM) would be important if there was evidence to support the utility of measured drug concentrations in making changes to dose…
Abstract Number: 1889 • 2019 ACR/ARP Annual Meeting
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Julio Ramirez¹, Andrea Cuervo Aguilera ², Raquel Celis ³, Virginia Ruiz-Esquide ³, Raul Castellanos-Moreira ⁴, Jose Gomez-Puerta ⁵, Raimon Sanmarti ⁵ and Juan Cañete ⁵, ¹Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Hospital Clínic Barcelona, Spain, Barcelona, Spain, ³Hospital Clínic, Barcelona, Spain, ⁴Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remissionMethods: RA patients in clinical remission (defined as DAS28-ESR…
Abstract Number: 2005 • 2019 ACR/ARP Annual Meeting
Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis
Bhargavi Duvvuri¹ and Christian Lood ¹, ¹University of Washington, Seattle
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune inflammatory disease causing erosive and disabling joint damage. We recently found that mitochondria are extruded upon formation of…
Abstract Number: 2163 • 2019 ACR/ARP Annual Meeting
Prevalence of Postoperative Anemia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Undergoing Total Knee Arthroplasty: A Study of National Inpatient Sample 2010-2014
Karan Jatwani ¹, Karan Chugh ², Bikramjit Bindra ³ and Shraddha Jatwani², ¹Mount Sinai West - St Luke’s Hospital, New York, ²St. Vincent Evansville, Evansville, ³Government Medical College & Hospital, Chandigarh, India
Background/Purpose: Total knee arthroplasty (TKA) is a valuable option for improving function and pain control in patients with end-stage arthritis, especially those with inflammatory arthritis…
Abstract Number: 2302 • 2019 ACR/ARP Annual Meeting
Comparison Between Fibromyalgia and Neuropathic Pain in Patients with Established Rheumatoid Arthritis
Yong Gil Hwang¹, Lei Zhu ¹ and Larry Moreland ¹, ¹University of Pittsburgh, PITTSBURGH, PA
Background/Purpose: Our objectives were (1) to identify similarities and differences of pain symptoms identified by fibromyalgia (FM) and neuropathic pain (NP) screening tool (2) to…
Abstract Number: 2323 • 2019 ACR/ARP Annual Meeting
The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Sicong Huang ¹, Zeling He ¹, Daniel Solomon ², Elena Massarotti ³, Charlotte Golnik ¹, Thany Seyok ¹, Seth Brownmiller ⁴, Tianrun Cai ³, Nicole Yang ³, Laurel Campbell ³, Leanne Barrett ³, Courtney Bibbo ³, Kenneth Pariser ³, Derrick Todd ³, Marcy Bolster ⁴, Marcelo Di Carli ³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: Inflammation accounts for much of the excess cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). We hypothesize that increased systemic inflammation leads to…
Abstract Number: 2342 • 2019 ACR/ARP Annual Meeting
Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study
Jeong Seok Lee¹, Young Im Yoon ², Eun Young Lee ³, Jung Yoon Choe ⁴, Hwa Jung Lee ⁵, Yong-Beom Park ⁶, Eun Ha Kang ⁷, You-Jung Ha ⁷, Yeon-Ah Lee ⁸ and Seong Hye Jang ⁹, ¹Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ⁴Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, ⁵DAEGU CATHOLIC UNIVERSITY, Daegu, Republic of Korea, ⁶Yonsei university college of medicine, severance hospital, Seodaemun-gu, Seoul-t'ukpyolsi, Republic of Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁸School of Medicine, Kyung Hee University, Seoul, Republic of Korea, ⁹Soonchunhyang University, Cheonan, Republic of Korea
Background/Purpose: Interstitial lung disease (ILD) is the most common lung disease among rheumatoid arthritis (RA) patients. Although the overall mortality rates for RA have decreased…
Abstract Number: 2368 • 2019 ACR/ARP Annual Meeting
Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study
Claire Rempenault¹, Cédric Lukas ¹, Bernard Combe ², Isabelle Pane ³, Xavier Mariette ⁴, Jacques-Eric Gottenberg ⁵ and Jacques Morel ¹, ¹Department of Rheumatology, Montpellier University Hospital, Montpellier, France, Montpellier, Languedoc-Roussillon, France, ²CHU Montpellier, Montpellier University, Montpellier, France, ³Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris, France., Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Several studies have reported an increased risk of gastro-intestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) compared to conventional synthetic…
Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
Abstract Number: 2805 • 2019 ACR/ARP Annual Meeting
Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls
Noha Elemam¹, Mahmood Hachim ¹, Suad Hannawi ² and Azzam Maghazachi ¹, ¹Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, Sharjah, United Arab Emirates, ²Ministry of Health and Prevention-UAE, Department of Rheumatology, Dubai, United Arab Emirates
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune diseases (1-3% of the world’s population). RA is a prototypic inflammatory disease, being characterized by an…
Abstract Number: 2906 • 2019 ACR/ARP Annual Meeting
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Elise van Mulligen¹, Angelique Weel ², Martijn Kuijper ², Mieke Hazes ¹, Annette van der Helm-van Mil ³ and Pascal de Jong ¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: In rheumatoid arthritis (RA) disease outcomes have improved enormously in the last decades. Due to early initiation of therapy, a treat-to-target approach and a…
Abstract Number: 2823 • 2019 ACR/ARP Annual Meeting
Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting
Jill Norris¹, Elizabeth Bemis ², Marie Feser ³, M. Kristen Demoruelle ⁴, Jennifer Seifert ⁵, Michael Weisman ⁶, Jane Buckner ⁷, Peter Gregersen ⁸, Ted Mikuls ⁹, James O'Dell ⁹, Richard M. Keating ¹⁰, Kevin Deane ³ and V. Michael Holers ⁵, ¹Colorado School of Public Health, Aurora, ²University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Benaroya Research Institute, Seattle, WA, ⁸Feinstein Institutes for Medical Research, Manhasset, NY, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰Scrippshealth, La Jolla
Background/Purpose: Rheumatoid arthritis (RA)-related autoantibodies are typically elevated prior to the onset of seropositive RA. Screening for autoantibody (aAb) positive individuals is a means to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].